Synthesis, radiolabeling, and biodistribution evaluation of novel hyperbranched polyglycerols-based radiotracers for targeting PSMA in prostate cancer

Articles in Press

Document Type : Original Article

Authors

1 Department of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

2 Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Mechanical Engineering, Shiraz University of Technology, Shiraz, Iran

4 Department of Pharmaceutical Chemistry and Radiopharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

10.22038/ijbms.2026.94567.20396

Abstract

Objective(s): Prostate-specific membrane antigen (PSMA) is a valuable target for prostate cancer imaging and therapy. This study aimed to improve the rapid blood clearance and suboptimal tumor uptake and retention of radiolabeled PSMA by developing a hyperbranched polyglycerol (HPG)-based PSMA conjugate.
Materials and Methods: HPG was synthesized via a one-step ring-opening multibranching polymerization (ROMBP) technique and sequentially functionalized with a PSMA-targeting ligand and a tris (hydroxypyridinone) (THP) chelator. The final construct was radiolabeled with gallium-68 or technetium-99m. Physicochemical properties, including lipophilicity (log P) and in vitro stability, were evaluated. In vivo biodistribution and imaging were assessed in LNCaP tumor-bearing nude mice using PET/SPECT/CT.
Results: The THP-HPGs-PSMA derivative (170 kDa, 5-6 PSMA ligands, and 7-8 THP chelators per polymer molecule) achieved radiochemical purity >99%. [68Ga]Ga THP HPG PSMA had high stability (>95% after 120 min), and log P of -1.56 ± 0.18. Blood uptake was 13.95 ± 0.75 and 11.82 ± 0.88 %ID/g at 30 and 120 min, respectively. Tumor uptake reached 7.12 ± 0.27, 7.40 ± 0.63, and 7.91 ± 0.20 %ID/g at 30, 60, and 120 min, respectively. Clearance was predominantly hepatobiliary with reduced renal excretion. [⁹⁹ᵐTc]Tc-THP-HPG-PSMA showed tumor uptake of 8.74 ± 0.25, 9.41 ± 0.42, and 9.80 ± 0.41 %ID/g at 4, 8, and 16 hr. Blocking studies reduced tumor uptake from 7.12 ± 0.27 to 0.93 ± 0.53 %ID/g.
Conclusion: Radiolabeled THP-HPG-PSMA demonstrates improved pharmacokinetics, enhanced tumor uptake, prolonged tumor retention, and favorable tumor-to-blood ratios, indicating strong potential for PSMA-targeted prostate cancer applications.

Keywords

Main Subjects

References

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17-48.
2.    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
3.    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
4.    Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches. Molecules 2022;27:5730.
5.    Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249.
6.    Sartor O, De Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385:1091-103.
7.    Descotes J-L. Diagnosis of prostate cancer. Asian J Urol 2019;6:129-136.
8.    Vakili S, Beheshti I, Barzegar Behrooz A, Łos MJ, Vitorino R, Ghavami S. Transforming prostate cancer care: Innovations in diagnosis, treatment, and future directions. Int J Mol Sci 2025;26:5386.
9.    Adnan A, Basu S. PSMA receptor-based PET-CT: The basics and current status in clinical and research applications. Diagnostics 2023;13:158.
10.    Houshmand S, Lawhn-Heath C, Behr S. PSMA PET imaging in the diagnosis and management of prostate cancer. Abdom Radiol (NY) 2023;48:3610-3623.
11.    Hennrich U, Eder M. [68Ga]Ga-PSMA-11: The first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals 2021;14:713.
12.    Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): The first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals 2022;15:1292.
13.    Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697-705.
14.    Sandgren K, Johansson L, Axelsson J, Jonsson J, Ögren M, Ögren M, et al. Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients. EJNMMI Phys 2019;6:2.
15.    Benesova M, Umbricht CA, Schibli R, Müller C. Albumin-binding PSMA ligands: Optimization of the tissue distribution profile. Mol Pharm 2018;15:934-946.
16.    Boinapally S, Alati S, Jiang Z, Yan Y, Lisok A, Singh R, et al. Preclinical evaluation of a new series of albumin-binding 177Lu-labeled PSMA-based low-molecular-weight radiotherapeutics. Molecules 2023;28:6158.
17.    Abbina S, Vappala S, Kumar P, Siren EM, La CC, Abbasi U, et al. Hyperbranched polyglycerols: recent advances in synthesis, biocompatibility and biomedical applications. J Mater Chem B 2017;5:9249-9277.
18.    Kainthan RK, Hester SR, Levin E, Devine DV, Brooks DE. In vitro biological evaluation of high molecular weight hyperbranched polyglycerols. Biomaterials 2007;28:4581-4590.
19.    Pouyan P, Cherri M, Haag R. Polyglycerols as multi-functional platforms: Synthesis and biomedical applications. Polymers 2022;14:2684.
20.    Bohrmann L, Burghardt T, Rodriguez-Rodriguez C, Herth MM, Saatchi K, Hafeli UO. Quantitative evaluation of a multimodal Aptamer-Targeted Long-Circulating polymer for tumor targeting. ACS Omega 2023;8:11003-11020.
21.    Saatchi K, Bénard F, Hundal N, Grimes J, Shcherbinin S, Pourghiasian M, et al. Preclinical PET Imaging and Toxicity Study of a 68Ga-Functionalized Polymeric Cardiac Blood Pool Agent. Pharmaceutics 2023;15:767.
22.    Saatchi K, Gelder N, Gershkovich P, Sivak O, Wasan KM, Kainthan RK, et al. Long-circulating non-toxic blood pool imaging agent based on hyperbranched polyglycerols. Int J Pharm 2012;422:418-27.
23.    Hamilton JL, Imran ul-haq M, Abbina S, Kalathottukaren MT, Lai BF, Hatef A, et al. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator. Biomaterials 2016;102:58-71.
24.    Imran ul-haq M, Lai BF, Chapanian R, Kizhakkedathu JN. Influence of architecture of high molecular weight linear and branched polyglycerols on their biocompatibility and biodistribution. Biomaterials 2012;33:9135-9147.
25.    Hu M, Chen M, Li G, Pang Y, Wang D, Wu J, et al. Biodegradable hyperbranched polyglycerol with ester linkages for drug delivery. Biomacromolecules 2012;13:3552-3561.
26.    Schmitt V, Rodríguez-Rodríguez C, Hamilton J, Shenoi R, Schaffer P, Sossi V, et al. Quantitative SPECT imaging and biodistribution point to molecular weight independent tumor uptake for some long-circulating polymer nanocarriers. RSC Adv 2018;8:5586-5595.
27.    Shenoi RA, Lai BF, Kizhakkedathu JN. Synthesis, characterization, and biocompatibility of biodegradable hyperbranched polyglycerols from acid-cleavable ketal group functionalized initiators. Biomacromolecules. 2012;13:3018-3030.
28.    Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev 2014;43:260-290.
29.    Kainthan RK, Muliawan EB, Hatzikiriakos SG, Brooks DE. Synthesis, characterization, and viscoelastic properties of high molecular weight hyperbranched polyglycerols. Macromolecules 2006;39:7708-7717.
30.    Gholipour N, Akhlaghi M, Mokhtari Kheirabadi A, Fasihi Ramandi M, Farashahi A, Beiki D, et al. Development of a novel 68Ga-dextran carboxylate derivative for blood pool imaging. Radiochim Acta 2019;107:233-242.
31.    Leguy J. Periodate oxidation of cellulose for internal plasticization and materials design. Université Grenoble Alpes; 2018.
32.    Abbina S, Gill A, Mathew S, Abbasi U, Kizhakkedathu JN. Polyglycerol-based macromolecular iron chelator adjuvants for antibiotics to treat drug-resistant bacteria. ACS Appl Mater Interfaces. 2020;12:37834-37844.
33.    Buchwalder C, Jaraquemada-Pelaez MdG, Rousseau J, Merkens H, Rodriguez-Rodriguez C, Orvig C, et al. Evaluation of the tetrakis (3-Hydroxy-4-Pyridinone) Ligand THPN with Zirconium (IV): Thermodynamic solution studies, bifunctionalization, and in vivo assessment of macromolecular 89Zr-THPN-conjugates. Inorg Chem 2019;58:14667-14681.
34.    Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and in vivo characterization of 64Cu-labeled AbegrinTM, a humanized monoclonal antibody against integrin αvβ3. Cancer Res 2006;66:9673-9681.
35.    Jokar S, Behnammanesh H, Erfani M, Sharifzadeh M, Gholami M, Sabzevari O, et al. Synthesis, biological evaluation and preclinical study of a novel 99mTc-peptide: A targeting probe of amyloid-β plaques as a possible diagnostic agent for Alzheimer’s disease. Bioorg Chem 2020;99:103857.
36.    Gholipour N, Akhlaghi M, Kheirabadi AM, Geramifar P, Beiki D. Development of Ga-68 labeled, biotinylated thiosemicarbazone dextran-coated iron oxide nanoparticles as multimodal PET/MRI probe. Int J Biol Macromol 2020;148:932-941.
37.    Belkahla S, Nahvi I, Biswas S, Nahvi I, Ben Amor N. Advances and development of prostate cancer, treatment, and strategies: A systemic review. Front Cell Dev Biol 2022;10:991330.
38.    Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, et al. Prevention and early detection of prostate cancer. Lancet Oncol 2014;15:e484-492.
39.    Albisinni S, Aoun F, Marcelis Q, Jungels C, Al Hajj Obeid W, Zanaty M, et al. Innovations in imaging modalities for recurrent and metastatic prostate cancer: A systematic review. Minerva Urol Nefrol 2018;70:252-270.
40.    Volpe F, Nappi C, Piscopo L, Zampella E, Mainolfi CG, Ponsiglione A, et al. Emerging role of nuclear medicine in prostate cancer: Current state and future perspectives. Cancers 2023;15:4746.
41.    Ismuha RR, Ritawidya R, Daruwati I, Muchtaridi M. Future prospect of low-molecular-weight prostate-specific membrane antigen radioisotopes labeled as theranostic agents for metastatic castration-resistant prostate cancer. Molecules 2024;29:6062.
42.    Plichta KA, Graves SA, Buatti JM. Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer. Int J Mol Sci 2021;22:12095.
43.    Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, et al. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Res 2022;12:65.
44.    Banerjee SR, Pullambhatla M, Shallal H, Lisok A, Mease RC, Pomper MG. A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). Oncotarget 2011;2:1244-1253.
45.    Sharma P, Negi P, Mahindroo N. Recent advances in polymeric drug delivery carrier systems. Adv Polym Biomed Appl 2018;10:369-88.
46.    Pant K, Sedláček O, Nadar RA, Hrubý M, Stephan H. Radiolabelled polymeric materials for imaging and treatment of cancer: quo vadis? Adv Healthc Mater 2017;6:1601115.
47.    Peltek OO, Muslimov AR, Zyuzin MV, Timin AS. Current outlook on radionuclide delivery systems: from design consideration to translation into clinics. J Nanobiotechnology 2019;17:90.
48.    Meher N, VanBrocklin HF, Wilson DM, Flavell RR. PSMA-targeted nanotheranostics for imaging and radiotherapy of prostate cancer. Pharmaceuticals 2023;16:315.
49.    Sunder A, Frey H, Mülhaupt R. Hyperbranched polyglycerols by ring-opening multibranching polymerization. Macromol Symp 2000;163:1-12.
50.    Wilms D, Stiriba S-E, Frey H. Hyperbranched polyglycerols: from the controlled synthesis of biocompatible polyether polyols to multipurpose applications. Acc Chem Res 2010;43:129-141.
51.    Jafari M, Abolmaali SS, Najafi H, Tamaddon AM. Hyperbranched polyglycerol nanostructures for anti-biofouling, multifunctional drug delivery, bioimaging and theranostic applications. Int J Pharm 2020;576:118959.
52.    Marasini N, Fu C, Fletcher NL, Subasic C, Er G, Mardon K, et al. The impact of polymer size and cleavability on the intravenous pharmacokinetics of PEG-based hyperbranched polymers in rats. Nanomaterials 2020;10:2452.
53.    Nawaz S, Mullen GE, Sunassee K, Bordoloi J, Blower PJ, Ballinger JR. Simple, mild, one-step labelling of proteins with gallium-68 using a tris (hydroxypyridinone) bifunctional chelator: A 68Ga-THP-scFv targeting the prostate-specific membrane antigen. EJNMMI Res 2017;7:86.
54.    Aranda-Lara L, García BEO, Isaac-Olivé K, Ferro-Flores G, Meléndez-Alafort L, Morales-Avila E. Drug Delivery Systems-Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy. Macromol Biosci 2021;21:2000362.
55.    Dikpati A, Maio VDP, Ates E, Greffard K, Bertrand N. Studying the stability of polymer nanoparticles by size exclusion chromatography of radioactive polymers. J Control Release 2024;369:394-403.
56.    Ioppolo JA, Nezich RA, Richardson KL, Morandeau L, Leedman PJ, Price RI. Direct in vivo comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 and [18F]AlF-PSMA-11 in mice bearing PSMA-expressing xenografts. Appl Radiat Isot 2020;161:109164.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 26 May 2026

Files

Share

How to cite

Statistics